



Press release 2015-10-19

Order for eight C-RAD systems from Italy

C-RADs Italian distributor – TecnoSan S.a.s – secured an order for four Catalyst™ systems as well as four Sentinel™ 4DCT systems, to be installed in three cancer treatment clinics in the Campania region in southern Italy.

The Catalysts will be delivered with the complete software configuration containing modules for Respiratory Gating, Patient Setup and Positioning, and Motion Monitoring, as well as interfaces to Elekta Versa HD linear accelerators. The customer also decided on the unique audio-visual couching functionality that supports an interactive gating mode.

The systems will be installed in three different cancer treatment centers in the Campania region operated by So.Re.Sa – a regional healthcare company. One of the centers, Ospedale Giuseppe Moscati in Avellino, will receive two Catalyst systems and two Sentinel systems.

Delivery of the systems is scheduled for the fourth quarter of 2015, and they are expected to be operational and ready for patients at the beginning of 2016. C-RAD booked the order in the third quarter.

“This is a very important result, since the increased complexity of radiation therapy requires more sophisticated tools to give patients the best possible treatment,” says Dr. Mattia Dell’Orsola, Sales and Marketing Manager at TecnoSan. “We are very proud that Elekta and So.Re.Sa. have chosen us to help them achieve this goal with C-RAD’s solutions. In just a few months we will have 15 C-RAD systems in clinical use in Italy.”

The Catalyst and Sentinel systems offer the required technology to perform high-end treatment techniques within radiation therapy. With this solution C-RAD supports the whole 4D treatment chain from imaging to delivery. Respiratory gated treatments are frequently used when the target volume is close to cardiac tissue or for special treatments in which the tumor position depends on the respiratory cycle.

At the end of October, Ospedale Santa Maria Annunziata in Florence, Italy – a C-RAD customer – will host a symposium dedicated to surface tracking in radiation therapy. Participants from radiation therapy centers from various sites in Italy are expected.

“Thanks to the excellent work by our distributor, we were able to secure this important order,” says Tim Thurn, CEO of C-RAD. “After two challenging years we have seen a recovery of the Italian radiation therapy market this year, and we expect this positive trend to continue through 2016. The symposium in Florence shows the strong interest within the Italian radiation therapy community for surface tracking products. As the market leader in optical patient positioning, this is a good platform for C-RAD to further grow and serve the market with these vital radiation therapy tools.”

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala,



Sweden. Employees currently number 39. C-RAD's business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are being integrated. C-RAD AB is listed on NASDAQ Stockholm. For more information on C-RAD, please visit www.c-rad.com.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).